Sara Donati

Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors

Alessandra Gennari, B. Salvadori, Sara Donati et al. · Journal of Clinical Oncology · 1999 · 114 citations

Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients

Alessandra Gennari, Sara Donati, B. Salvadori et al. · Clinical Breast Cancer · 2000 · 102 citations · Full text

Positron Emission Tomography, Breast Oncology, Oncologic Imaging +10

Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years

Valentina Guarneri, Sara Donati, Massimiliano Nicolini et al. · The Oncologist · 2005 · 87 citations · Full text

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

Pierfranco Conté, Alessandra Gennari, Sara Donati et al. · Breast Cancer Research and Treatment · 2001 · 72 citations · Full text

Advanced Breast Cancer, Breast Oncology, Medicine +7